Bayer's Apollo Deal Is Done — Now the Quarter Has to Speak
Published on 10/11/2026 at 16:31 | Editorial boerse-global.de
Bayer shares closed Friday's session 2.0% higher, placing the stock among the DAX's stronger performers. The advance came against a friendlier market backdrop, but it also coincided with a completed corporate transaction — a distinction that matters more than the headline gain itself.
A minority stake, not a takeover
Apollo has taken a minority interest in LARC. The deal is closed, not merely announced and awaiting execution — which sets it apart from Bayer's other recent news, including the investment plans on the pharmaceutical side that remain proposals rather than finished business.
The size of the transaction deserves careful reading. The figure attached to the deal describes the stake purchase; it is neither a revenue line nor a profit metric, and it should not be treated as a gauge of operating performance. What the market got on Friday was a concrete corporate event, though that does not mean it fully accounts for the day's gain. The broader tape was working in Bayer's favor too.
The tape did part of the work
German equities found support from falling oil prices and easing market yields, according to media reports, with calmer risk sentiment and a well-received US Treasury auction adding to the recovery. None of that is Bayer-specific news. Two separate layers therefore sit behind Friday's move: the Apollo stake as the company-level catalyst, and the improved market environment as the background. Both belong to the day's trading, but they should not be folded into a single corporate headline.
Should investors sell immediately? Or is it worth buying Bayer?
Pharma keeps its own calendar
Bayer's drug pipeline remains a distinct news thread. The US FDA has accepted the company's supplemental application for Finerenon in chronic kidney disease without diabetes, based on positive Phase III data from the FIND-CKD trial. Acceptance is not approval, and that gap is worth keeping in view.
A second regulatory item: on September 28, the FDA granted Lynkuet a priority review for an additional indication covering moderate-to-severe vasomotor symptoms in women on endocrine therapy for hormone receptor-positive breast cancer. Separately, roughly a week ago, Bayer announced a new drug manufacturing site in New Albany, Ohio, carrying a planned investment of USD 2.2 billion and around 600 new jobs. That project is a stated plan; the Apollo transaction is finished business. The difference is precisely what makes the stake sale the more relevant item for assessing Friday's trading.
JPMorgan's note sets the real test
None of this answers the operating question. JPMorgan kept Bayer at "Overweight" with a price target of EUR 61 on October 1, but analyst Richard Vosser cautioned that early market expectations for the third quarter may be too high. He attributed the possible shortfall mainly to timing effects in the agricultural division, and on that basis expects full-year estimates to barely move. His argument separates a potentially soft quarter from any fundamental deterioration in the annual outlook.
Bayer at a turning point? This analysis reveals what investors need to know now.
Results for the third quarter of 2026 are scheduled for November 3. The positive rating, in other words, is not an unconditional green light for that report. What matters is whether any drag proves genuinely temporary — and Friday's friendly session does not pre-empt that verdict. Market sentiment helped for a day; the operational reckoning still lies ahead.
Ad
Bayer Stock: New Analysis - 11 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
